Clinical trial and in-vitro study comparing the efficacy of treating bony lesions with allografts versus synthetic or highly-processed xenogeneic bone grafts

Table 1 Epidemiological and characterizing parameters

	Allogenic cancellous bone (ACB)	N	Synthetic bone substitutes (SBS)	N	P
Age	62.6 ± 19.6	116	55.8 ± 16.3	116	0.004^a
Gender (f/m)	62/54	116	55/61	116	n.s.^b
ASA	2.31 ± 0.72	116	1.95 ± 0.67	116	<0.0001^c
Defect size	20.21 ± 21.00	114	5.75 ± 8.33	115	<0.0001^a
BMI	26.01 ± 5.15	116	26.99 ± 5.60	116	n.s.^a
Consolidation time (months)	3.93 ± 2.45	104	3.16 ± 3.31	107	n.s.^d
Complication rate	17 (14.6 %)	116	16 (13.8 %)	116	n.s.^b
Healing rate	104 (89.7 %)	116	107 (92.2 %)	116	n.s.^b

Overview about the epidemiological and characterizing parameters comparing both intervention groups, f female, m male, ASA physical status according to the American Society of Anesthesiologists, BMI body mass index, n.s. – not significant, ^a t-Test, ^b χ ²-Test, ^c U-Test (Mann und Whitney), ^dAspin-Welch-Test

ISSN: 1471-2474